Juliana Souza Ribeiro Costa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Juliana Souza Ribeiro Costa has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Laura Oliveira-Nascimento
Laboratory of Pharmaceutical Technology (Latef), Faculty of Pharmaceutical Sciences, State University of Campinas, Campinas, Brazil
7 shared publications - Renata Carvalho Feitosa
Laboratory of Pharmaceutical Technology and Biotechnology, Department of Pharmacy, Federal University of Rio Grande do Norte—UFRN, Natal 59012-570, RN, Brazil
3 shared publications - Claudia Garnero
Departamento de Ciencias Farmacéuticas, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Unidad de Investigación y Desarrollo en Tecnología Farmacéutica (UNITEFA) CONICET-UNC, Córdoba X5000HUA, Argentina
2 shared publications - Edvaldo Sabadini
Institute of Chemistry, University of Campinas, UNICAMP, Brazil
2 shared publications - Eneida de Paula
Department of Biochemistry and Tissue Biology, Institute of Biology, University of Campinas (UNICAMP), Campinas-SP, Brazil
2 shared publications - Fernando Bonin Okasaki
Faculdade de Engenharia Mecânica, Universidade Estadual de Campinas (UNICAMP), Campinas, São Paulo, Brazil
2 shared publications
Latest Publications
- Open Access
- 21 November 2023
- Published by Universidade Estadual de Campinas
Development of freeze-dried dosage forms for local delivery of anti-inflammatory molecules
- 21 November 2023
- Published by Universidade Estadual de Campinas
Open AccessDevelopment of freeze-dried dosage forms for local delivery of anti-inflammatory molecules
- Open Access
- 19 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1285
Supramolecular Arrangement of Doxycycline with Sulfobutylether-β-Cyclodextrin: Impact on Nanostructuration with Chitosan, Drug Degradation and Antimicrobial Potency
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. The inclusion of drugs in cyclodextrin complexes and their loading into nanocarriers can overcome these limitations. Thus, we studied the DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complex for the first time and used it to reticulate chitosan. The resulting particles were evaluated by their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction, and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM, and drug content. The partial inclusion of the DX molecule in CD happened in a 1:1 proportion and brought increased stability to solid DX upon thermal degradation. Chitosan-complex nanoparticles measured approximately 200 nm, with a narrow polydispersity and particles with sufficient drug encapsulation for microbiological studies. Both formulations preserved the antimicrobial activity of DX against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae, indicating the potential use of these formulations as drug delivery systems to treat local infections.
- 19 April 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (4) , 1285
Open AccessSupramolecular Arrangement of Doxycycline with Sulfobutylether-β-Cyclodextrin: Impact on Nanostructuration with Chitosan, Drug Degradation and Antimicrobial Potency
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. The inclusion of drugs in cyclodextrin complexes and their loading into nanocarriers can overcome these limitations. Thus, we studied the DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complex for the first time and used it to reticulate chitosan. The resulting particles were evaluated by their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction, and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM, and drug content. The partial inclusion of the DX molecule in CD happened in a 1:1 proportion and brought increased stability to solid DX upon thermal degradation. Chitosan-complex nanoparticles measured approximately 200 nm, with a narrow polydispersity and particles with sufficient drug encapsulation for microbiological studies. Both formulations preserved the antimicrobial activity of DX against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae, indicating the potential use of these formulations as drug delivery systems to treat local infections.
- Open Access
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Exploring Nanostructures for Doxycycline Delivery Based on Chitosan and Sulfobutylether-Β-Cyclodextrin
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. It is known that the inclusion of drugs in cyclodextrin complexes and their loading in nanocarriers can overcome these limitations. Thus, we developed DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complexes and DX-loaded nanoparticles, evaluating their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM and drug content. Complexes and chitosan nanoparticles presented approximately 200 nm size, narrow polydispersity and particles with sufficient drug encapsulation (25%) for microbiological studies. Both formulations showed antimicrobial activity against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae , indicating the potential use of these formulations as drug delivery systems to treat local infections.
- 1 January 2022
- Published by Elsevier in SSRN Electronic Journal
Open AccessExploring Nanostructures for Doxycycline Delivery Based on Chitosan and Sulfobutylether-Β-Cyclodextrin
Doxycycline (DX) is a well-established and broad-spectrum antimicrobial drug. However, DX has drawbacks, such as physicochemical instability in aqueous media and bacterial resistance. It is known that the inclusion of drugs in cyclodextrin complexes and their loading in nanocarriers can overcome these limitations. Thus, we developed DX/sulfobutylether-β-CD (SBE-β-CD) inclusion complexes and DX-loaded nanoparticles, evaluating their physicochemical characteristics and antibacterial activity. DX/SBE-β-CD complexes were characterized by nuclear magnetic resonance, infrared spectroscopy, thermal analysis, X-ray diffraction and scanning electron microscopy (SEM), whereas DX-loaded nanoparticles were characterized by dynamic light scattering, SEM and drug content. Complexes and chitosan nanoparticles presented approximately 200 nm size, narrow polydispersity and particles with sufficient drug encapsulation (25%) for microbiological studies. Both formulations showed antimicrobial activity against Staphylococcus aureus, whereas DX/SBE-β-CD inclusion complexes were also active against Klebsiella pneumoniae , indicating the potential use of these formulations as drug delivery systems to treat local infections.
- 1 June 2021
- Published by Elsevier in Sustainable Chemistry and Pharmacy
- Vol. 21
Sustainability of blisters for medicines in tablet form
- 1 June 2021
- Published by Elsevier in Sustainable Chemistry and Pharmacy
- Vol. 21
Sustainability of blisters for medicines in tablet form
- Open Access
- 10 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5741
Capsaicin-Cyclodextrin Complex Enhances Mepivacaine Targeting and Improves Local Anesthesia in Inflamed Tissues
Acidic environments, such as in inflamed tissues, favor the charged form of local anesthetics (LA). Hence, these drugs show less cell permeation and diminished potency. Since the analgesic capsaicin (CAP) triggers opening of the TRPV1 receptor pore, its combination with LAs could result in better uptake and improved anesthesia. We tested the above hypothesis and report here for the first time the analgesia effect of a two-drug combination (LA and CAP) on an inflamed tissue. First, CAP solubility increased up to 20 times with hydroxypropyl-beta-cyclodextrin (HP-β-CD), as shown by the phase solubility study. The resulting complex (HP-β-CD-CAP) showed 1:1 stoichiometry and high association constant, according to phase-solubility diagrams and isothermal titration calorimetry data. The inclusion complex formation was also confirmed and characterized by differential scanning calorimetry (DSC), X-ray diffraction, and 1H-NMR. The freeze-dried complex showed physicochemical stability for at least 12 months. To test in vivo performance, we used a pain model based on mouse paw edema. Results showed that 2% mepivacaine injection failed to anesthetize mice inflamed paw, but its combination with complexed CAP resulted in pain control up to 45 min. These promising results encourages deeper research of CAP as an adjuvant for anesthesia in inflamed tissues and cyclodextrin as a solubilizing agent for targeting molecules in drug delivery.
- 10 August 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (16) , 5741
Open AccessCapsaicin-Cyclodextrin Complex Enhances Mepivacaine Targeting and Improves Local Anesthesia in Inflamed Tissues
Acidic environments, such as in inflamed tissues, favor the charged form of local anesthetics (LA). Hence, these drugs show less cell permeation and diminished potency. Since the analgesic capsaicin (CAP) triggers opening of the TRPV1 receptor pore, its combination with LAs could result in better uptake and improved anesthesia. We tested the above hypothesis and report here for the first time the analgesia effect of a two-drug combination (LA and CAP) on an inflamed tissue. First, CAP solubility increased up to 20 times with hydroxypropyl-beta-cyclodextrin (HP-β-CD), as shown by the phase solubility study. The resulting complex (HP-β-CD-CAP) showed 1:1 stoichiometry and high association constant, according to phase-solubility diagrams and isothermal titration calorimetry data. The inclusion complex formation was also confirmed and characterized by differential scanning calorimetry (DSC), X-ray diffraction, and 1H-NMR. The freeze-dried complex showed physicochemical stability for at least 12 months. To test in vivo performance, we used a pain model based on mouse paw edema. Results showed that 2% mepivacaine injection failed to anesthetize mice inflamed paw, but its combination with complexed CAP resulted in pain control up to 45 min. These promising results encourages deeper research of CAP as an adjuvant for anesthesia in inflamed tissues and cyclodextrin as a solubilizing agent for targeting molecules in drug delivery.
- Open Access
- 1 November 2019
- Published by Elsevier in Journal of Advanced Research
- Vol. 20, 33-41
A mini-review on drug delivery through wafer technology: Formulation and manufacturing of buccal and oral lyophilizates
- 1 November 2019
- Published by Elsevier in Journal of Advanced Research
- Vol. 20, 33-41
Open AccessA mini-review on drug delivery through wafer technology: Formulation and manufacturing of buccal and oral lyophilizates
- Open Access
- 24 September 2019
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1057
Pharmacokinetic Aspects of Nanoparticle-in-Matrix Drug Delivery Systems for Oral/Buccal Delivery
Oral route maintains its predominance among the ones used for drug delivery, especially when medicines are self-administered. If the dosage form is solid, therapy gains in dose precision and drug stability. Yet, some active pharmaceutical substances do not present the required solubility, permeability or release profile for incorporation into traditional matrices. The combination of nanostructured drugs (NP) with these matrices is a new and little-explored alternative, which could bring several benefits. Therefore, this review focused on combined delivery systems based on nanostructures to administer drugs by the oral cavity, intended for buccal, sublingual, gastric or intestinal absorption. We analyzed published NP-in-matrix systems and compared main formulation characteristics, pharmacokinetics, release profiles and physicochemical stability improvements. The reported formulations are mainly semisolid or solid polymers, with polymeric or lipid nanoparticles and one active pharmaceutical ingredient. Regarding drug specifics, most of them are poorly permeable or greatly metabolized. The few studies with pharmacokinetics showed increased drug bioavailability and, sometimes, a controlled release rate. From our knowledge, the gathered data make up the first focused review of these trendy systems, which we believe will help to gain scientific deepness and future advancements in the field.
- 24 September 2019
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 1057
Open AccessPharmacokinetic Aspects of Nanoparticle-in-Matrix Drug Delivery Systems for Oral/Buccal Delivery
Oral route maintains its predominance among the ones used for drug delivery, especially when medicines are self-administered. If the dosage form is solid, therapy gains in dose precision and drug stability. Yet, some active pharmaceutical substances do not present the required solubility, permeability or release profile for incorporation into traditional matrices. The combination of nanostructured drugs (NP) with these matrices is a new and little-explored alternative, which could bring several benefits. Therefore, this review focused on combined delivery systems based on nanostructures to administer drugs by the oral cavity, intended for buccal, sublingual, gastric or intestinal absorption. We analyzed published NP-in-matrix systems and compared main formulation characteristics, pharmacokinetics, release profiles and physicochemical stability improvements. The reported formulations are mainly semisolid or solid polymers, with polymeric or lipid nanoparticles and one active pharmaceutical ingredient. Regarding drug specifics, most of them are poorly permeable or greatly metabolized. The few studies with pharmacokinetics showed increased drug bioavailability and, sometimes, a controlled release rate. From our knowledge, the gathered data make up the first focused review of these trendy systems, which we believe will help to gain scientific deepness and future advancements in the field.
- Open Access
- 24 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Excipient-excipient interactions in the development of nanocarriers: an innovative statistical approach for formulation decisions
Excipient interaction has become essential knowledge for rational formulation design of nanoparticles. Nanostructured lipid carriers (NLCs) include at least three types of excipient, which enhance excipient interaction possibilities and relevance. The present article introduces an alternative approach for evaluating a great number of excipients with few samples, using NLC as a model delivery system. This approach is based on two sequential experiments using Hall-2 experimental design and analysis of excipient interactions in respect to their physicochemical properties by multilevel statistics. NLCs were prepared using a hot emulsification-ultrasonication method with lidocaine and nine excipients (solid lipids, oils and surfactants). The evaluated parameters were z-average size (DLS), dispersity (DLS), zeta potential (electrophoretic mobility) and entrapment efficiency (HPLC). Cetyl palmitate, beeswax, castor oil, capric/caprylic acid and polysorbate 80 all presented larger effects amongst the studied factors as well as a clear pattern of synergistic interactions. Following the verified trends, we produced an optimized NLC that exhibited all desirable physicochemical characteristics and a modified drug release profile. Our results demonstrate the methodology’s robustness, which can be applied to other nanoparticles and establish a cost-effective excipient evaluation.
- 24 July 2019
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 1-10
Open AccessExcipient-excipient interactions in the development of nanocarriers: an innovative statistical approach for formulation decisions
Excipient interaction has become essential knowledge for rational formulation design of nanoparticles. Nanostructured lipid carriers (NLCs) include at least three types of excipient, which enhance excipient interaction possibilities and relevance. The present article introduces an alternative approach for evaluating a great number of excipients with few samples, using NLC as a model delivery system. This approach is based on two sequential experiments using Hall-2 experimental design and analysis of excipient interactions in respect to their physicochemical properties by multilevel statistics. NLCs were prepared using a hot emulsification-ultrasonication method with lidocaine and nine excipients (solid lipids, oils and surfactants). The evaluated parameters were z-average size (DLS), dispersity (DLS), zeta potential (electrophoretic mobility) and entrapment efficiency (HPLC). Cetyl palmitate, beeswax, castor oil, capric/caprylic acid and polysorbate 80 all presented larger effects amongst the studied factors as well as a clear pattern of synergistic interactions. Following the verified trends, we produced an optimized NLC that exhibited all desirable physicochemical characteristics and a modified drug release profile. Our results demonstrate the methodology’s robustness, which can be applied to other nanoparticles and establish a cost-effective excipient evaluation.
- Open Access
- 1 May 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (5) , e0007388
Biodegradable nanocarriers coated with polymyxin B: Evaluation of leishmanicidal and antibacterial potential
Most treatments of leishmaniasis require hospitalization and present side effects or parasite resistance; innovations in drug formulation/reposition can overcome these barriers and must be pursued to increase therapeutic alternatives. Therefore, we tested polymyxin B (polB) potential to kill Leishmania amazonensis, adsorbed or not in PBCA nanoparticles (PBCAnp), which could augment polB internalization in infected macrophages. PBCAnps were fabricated by anionic polymerization and analyzed by Dynamic Light Scattering (size, ζ potential), Nanoparticle Tracking Analysis (size/concentration), vertical diffusion cell (release rate), drug incorporation (indirect method, protein determination) and in vitro cell viability. Nanoparticles coated with polB (PBCAnp-polB) presented an adequate size of 261.5 ± 25.9 nm, low PDI and ζ of 1.79 ± 0.17 mV (stable for 45 days, at least). The 50% drug release from PBCAnp-polB was 6–7 times slower than the free polB, which favors a prolonged and desired release profile. Concerning in vitro evaluations, polB alone reduced in vitro amastigote infection of macrophages (10 μg/mL) without complete parasite elimination, even at higher concentrations. This behavior limits its future application to adjuvant leishmanicidal therapy or antimicrobial coating of carriers. The nanocarrier PBCAnp also presented leishmanicidal effect and surpassed polB activity; however, no antimicrobial activity was detected. PolB maintained its activity against E. coli, Pseudomonas and Klebsiella, adding antimicrobial properties to the nanoparticles. Thus, this coated drug delivery system, described for the first time, demonstrated antileishmanial and antimicrobial properties. The bactericidal feature helps with concomitant prevention/treatment of secondary infections that worst ulcers induced by cutaneous L. amazonensis, ultimately ending in disfiguring or disabling lesions. Cutaneous leishmaniasis form disfiguring lesions that leads to depression and social isolation. Both consequences result often in economic and education loss for communities already short on resources. The actual treatment aims to eliminate the protozoa disease-vector. Yet, it presents undesired effects or parasite resistance, besides the need for intravenous infusions and hospitalization. There is a few topical leishmanicidals but none with prolonged action. As highlighted, no ideal therapy exists; we must keep searching for alternatives, which includes new drugs, vehicles or therapies. For drugs, the most cost-effective way comprises testing approved molecules for other diseases, such as the antimicrobial polymyxin B (polB). Repositioning a drug has the added benefit of known safety profile and drawbacks, shortening and narrowing the research path. In turn, carriers can decrease side-effects and multiple dosing. They shield and/or improve drug targeting, which in this case means delivering inside macrophages infected with Leishmania. An example is poly (n-butyl cyanoacrylate) nanoparticles (PBCAnp), shown as an efficient carrier for targeting an extended drug release. Therefore, this work aimed to evaluate leishmanicidal and adjuvant properties of polB, alone and absorbed onto PBCAnp.
- 1 May 2019
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 13 (5) , e0007388
Open AccessBiodegradable nanocarriers coated with polymyxin B: Evaluation of leishmanicidal and antibacterial potential
Most treatments of leishmaniasis require hospitalization and present side effects or parasite resistance; innovations in drug formulation/reposition can overcome these barriers and must be pursued to increase therapeutic alternatives. Therefore, we tested polymyxin B (polB) potential to kill Leishmania amazonensis, adsorbed or not in PBCA nanoparticles (PBCAnp), which could augment polB internalization in infected macrophages. PBCAnps were fabricated by anionic polymerization and analyzed by Dynamic Light Scattering (size, ζ potential), Nanoparticle Tracking Analysis (size/concentration), vertical diffusion cell (release rate), drug incorporation (indirect method, protein determination) and in vitro cell viability. Nanoparticles coated with polB (PBCAnp-polB) presented an adequate size of 261.5 ± 25.9 nm, low PDI and ζ of 1.79 ± 0.17 mV (stable for 45 days, at least). The 50% drug release from PBCAnp-polB was 6–7 times slower than the free polB, which favors a prolonged and desired release profile. Concerning in vitro evaluations, polB alone reduced in vitro amastigote infection of macrophages (10 μg/mL) without complete parasite elimination, even at higher concentrations. This behavior limits its future application to adjuvant leishmanicidal therapy or antimicrobial coating of carriers. The nanocarrier PBCAnp also presented leishmanicidal effect and surpassed polB activity; however, no antimicrobial activity was detected. PolB maintained its activity against E. coli, Pseudomonas and Klebsiella, adding antimicrobial properties to the nanoparticles. Thus, this coated drug delivery system, described for the first time, demonstrated antileishmanial and antimicrobial properties. The bactericidal feature helps with concomitant prevention/treatment of secondary infections that worst ulcers induced by cutaneous L. amazonensis, ultimately ending in disfiguring or disabling lesions. Cutaneous leishmaniasis form disfiguring lesions that leads to depression and social isolation. Both consequences result often in economic and education loss for communities already short on resources. The actual treatment aims to eliminate the protozoa disease-vector. Yet, it presents undesired effects or parasite resistance, besides the need for intravenous infusions and hospitalization. There is a few topical leishmanicidals but none with prolonged action. As highlighted, no ideal therapy exists; we must keep searching for alternatives, which includes new drugs, vehicles or therapies. For drugs, the most cost-effective way comprises testing approved molecules for other diseases, such as the antimicrobial polymyxin B (polB). Repositioning a drug has the added benefit of known safety profile and drawbacks, shortening and narrowing the research path. In turn, carriers can decrease side-effects and multiple dosing. They shield and/or improve drug targeting, which in this case means delivering inside macrophages infected with Leishmania. An example is poly (n-butyl cyanoacrylate) nanoparticles (PBCAnp), shown as an efficient carrier for targeting an extended drug release. Therefore, this work aimed to evaluate leishmanicidal and adjuvant properties of polB, alone and absorbed onto PBCAnp.
- 21 October 2017
- Published by PIBIC Unicamp
Polymeric nanocarriers for polymyxin B delivery